Phaseline

Targets › TBAT1

TBAT1: drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 3; Infectious disease; next expected readout Dec 2026.

Open in Phaseline: the race on TBAT1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Institute of Tropical Medicine, BelgiumAcoziborole
Adenosine transporter 1 (TbAT1) inhibitor for treatment of gambiense human African trypano
TBAT1Phase 3Trypanosomiasis; African, Due to Trypanosoma Brucei Gambiense, GambienseDec 2026

Conditions

Trypanosomiasis; African, Due to Trypanosoma Brucei Gambiense, Gambiense (1)

Modalities

small molecule (1)

Companies

Institute of Tropical Medicine, Belgium (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.